Clinical trial · Observational
Multi-academic Center Study of Xofigo Patients
A Retrospective, Longitudinal Multi-Center Study of Radium-223 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study will be conducted from a real-world perspective to describe treatment sequences involving radium-223 and chemotherapy in patients with metastatic castrate resistant prostate cancer (mCRPC) and assess overall survival (OS) associated with treatment sequences involving radium-223 and chemotherapy. While clinical trials of radium-223 has demonstrated a survival benefit in the treatment of mCRPC, both pre and post- docetaxel, study lacked exposure to second generation androgens and hence could not assess outcomes pre or post abiraterone or enzalutamide. The specific objective of this study is to describe and compare the clinical outcomes between treatment sequences for patients with mCRPC where 1) radium-223 is used (alone or in combination with abiraterone or enzalutamide) prior to chemotherapy versus 2) radium-223 used after chemotherapy in the treatment of mCRPC. The secondary objectives are to describe the safety patterns of docetaxel use among mCRPC patients who received chemotherapy post radium-223.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer, Castration Resistant | Castration-Resistant Prostate Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Jevtana | Drug | Cabazitaxel | ALIAS |
| Taxotere | Drug | Docetaxel | ALIAS |
| Xofigo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Ra-223 therapy before chemotherapy
- description
- Treatment sequence 1 will include all mCRPC patients who received Ra-223 alone or in combination with abiraterone or enzalutamide and subsequently received chemotherapy
- interventionNames
- Drug: Xofigo
- Drug: Taxotere
- Drug: Jevtana
- label
- Ra-223 after chemotherapy
- description
- Treatment sequence 2 includes all mCRPC patients who received chemotherapy before Radium 223 therapy
- interventionNames
- Drug: Xofigo
- Drug: Taxotere
- Drug: Jevtana
Primary outcomes (3)
- measure
- Overall survival
- timeFrame
- Up to 30 months
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Received at least one dose of radium-223 after mCRPC diagnosis * Received at least one prescription or dose of chemotherapy for treatment of mCRPC Exclusion Criteria: \- No documented visceral metastasis at initiation of radium-223
References
Publications (0)
Data not yet available